Important Safety Information: Ozempic is not for use in patients with type 1 diabetes or as a first-line therapy for type 2 diabetes
In response, CMS has proposed a reinterpretation of the statutory exclusion, distinguishing between drugs used for weight loss and those used for the treatment of obesity. This shift would allow Part D and state Medicaid coverage for anti-obesity medications (AOMs) prescribed specifically for obesity
Maybe I should have chosen a better job, but the people were great, I made some very good friends over there, Zlatin said
when he does drink, he consumes 1-2 alcoholic beverages In terms of lifestyle, JM reports that he could eat better and that he engages in limited physical activity (estimated at 30 minutes per week of light walking) Laboratory and vital findings : Weight : 232 pounds (body mass index [BMI] = 34 kg/m 2 ) Blood pressure : 128/84 mmHg (average of 3 seated blood pressure readings) Blood glucose : 116 mg/dL (fasting) Point-of-care A1C : 7.1% Serum creatinine : 1.5 mg/dL eGFR : 50 mL/min/1.73 m 2 Sodium : 139 mEq/L Potassium : 4.9 mEq/L UACR : 60 mg/g (microalbuminuria) Low-density lipoprotein cholesterol (LDL-C): 88 mg/dL High-density lipoprotein cholesterol (HDL-C): 40 mg/dL Triglycerides: 148 mg/dL Case discussion JM provided some important information that will be helpful when determining a treatment plan to minimize his cardiovascular risk
Additionally, the healthcare professional will discuss the potential risks and side effects associated with ipamorelin therapy, such as increased risk of disease, elevated cortisol levels, and fatigue
